Netherlands Proposes Tax Break for Innovative Startups Under Controversial Wealth Tax Reform

2026-04-30 community

The Hague, Thursday, 30 April 2026.
The Dutch government plans startup exemptions from its new box 3 wealth tax system, but critics argue the ‘innovativeness’ criteria are flawed and may exclude socially valuable companies while favoring scalable tech firms. The proposal emerges as lawmakers grapple with taxing illiquid assets like company shares.

Government Develops Startup Exemption Framework

The Dutch cabinet is actively developing a tax exemption for startups and scale-ups under the reformed box 3 wealth tax system in response to mounting criticism of the new framework [1]. Minister Heleen Herbert of Economic Affairs and Climate announced the exemption to prevent discouraging investment in innovative startups [1]. The proposal would exempt qualifying companies from the standard wealth tax treatment, instead taxing shares only upon actual sale rather than on paper value increases [4]. This legislative initiative represents the sixth or seventh attempt to create a favorable fiscal framework for employee participation in startup equity [5].

Assessment Criteria Spark Innovation Debate

Under the proposed system, the Netherlands Enterprise Agency (RVO) would assess companies using a point-based system to determine startup or scale-up qualification, requiring businesses to demonstrate a scalable and repeatable business model [3][4]. The government defines scalability as a company’s ability to rapidly increase revenue through technology without proportional increases in personnel and resources, primarily benefiting digital technologies [1]. However, critics argue these criteria create a somewhat random selection of companies and may favor venture capitalists focused on revenue and profit growth without proportional cost increases [1]. The emphasis on rapid scalability could exclude socially valuable companies operating in sectors where scaling up remains difficult, even with digital innovations [1].

Biotech Sector Faces Potential Exclusion

The proposed assessment framework may systematically exclude biotechnology companies due to their inherently long and expensive development processes that conflict with RVO’s scalability requirements [3]. Biotech firms typically require extensive product-specific clinical research phases that do not align with the government’s emphasis on rapid, repeatable business models [3]. Industry group Hollandbio suggests that a startup’s potential to make global societal and economic impact, along with its ability to attract private venture capital, should serve as key assessment criteria rather than speed and repeatability [3]. The organization argues that the current proposal favors Software-as-a-Service and fintech startups while potentially disadvantaging biotech companies that could deliver significant long-term societal benefits [3].

Implementation Timeline and Administrative Challenges

The tax exemption system is scheduled to take effect from 2028, coinciding with the implementation of the broader box 3 wealth tax reform [4][7]. Companies receiving positive RVO assessments would benefit from taxation only upon share realization rather than on growth, while qualifying employees would pay tax on only 65% of stock option benefits, creating an effective tax rate of approximately 32% [4]. However, Lucien Burm, chairman of the Dutch Startup Association, estimates that approximately 11,000 companies will require assessment under the proposed system, potentially causing significant delays and uncertainty [3]. The consultation period for stakeholder feedback closed on April 29, 2026 [3], and the State Secretary of Finance plans to submit the legislative proposal to Parliament in September 2026, targeting implementation of the reduced employee tax burden by January 1, 2027 [7].

Bronnen

innovation policy tax exemption